Call 855-808-4530 or email GroupSales@alm.com to receive your discount on a new subscription.
As of Jan. 7, 2004, pursuant to Section 1112 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, agreements between brand-name and generic pharmaceutical companies regarding the manufacture, marketing, and sale of generic versions of brand-name drug products are required to be filed with the Federal Trade Commission and the U.S. Department of Justice. In addition, certain agreements between generic drug manufacturers, each of which have filed certain types of applications with the FDA for the same brand-name drug product, must also be filed. However, agreements that concern only purchase orders for raw materials, equipment and facility contracts, employment or consulting contracts or packaging and labeling contracts need not be reported. The filing requirements cover agreements executed on or after Jan. 7, 2004.
Any agreement subject to the new law must be within 10 business days of the date the agreement was executed. The penalty for failure to file can be up to $11,000 per day.
The new requirements are being implemented because the FTC believes that agreements between brand-name and generic drug companies can have the effect of delaying entry to the market of generic drugs. Using these filings, the anti-trust agencies will be able to monitor the effects of these agreements on trade.
Copies of the new filing requirements can be found at www.ftc.gov.
As of Jan. 7, 2004, pursuant to Section 1112 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, agreements between brand-name and generic pharmaceutical companies regarding the manufacture, marketing, and sale of generic versions of brand-name drug products are required to be filed with the Federal Trade Commission and the U.S. Department of Justice. In addition, certain agreements between generic drug manufacturers, each of which have filed certain types of applications with the FDA for the same brand-name drug product, must also be filed. However, agreements that concern only purchase orders for raw materials, equipment and facility contracts, employment or consulting contracts or packaging and labeling contracts need not be reported. The filing requirements cover agreements executed on or after Jan. 7, 2004.
Any agreement subject to the new law must be within 10 business days of the date the agreement was executed. The penalty for failure to file can be up to $11,000 per day.
The new requirements are being implemented because the FTC believes that agreements between brand-name and generic drug companies can have the effect of delaying entry to the market of generic drugs. Using these filings, the anti-trust agencies will be able to monitor the effects of these agreements on trade.
Copies of the new filing requirements can be found at www.ftc.gov.
With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.
This article highlights how copyright law in the United Kingdom differs from U.S. copyright law, and points out differences that may be crucial to entertainment and media businesses familiar with U.S law that are interested in operating in the United Kingdom or under UK law. The article also briefly addresses contrasts in UK and U.S. trademark law.
The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.
Ideally, the objective of defining the role and responsibilities of Practice Group Leaders should be to establish just enough structure and accountability within their respective practice group to maximize the economic potential of the firm, while institutionalizing the principles of leadership and teamwork.
In Rockwell v. Despart, the New York Supreme Court, Third Department, recently revisited a recurring question: When may a landowner seek judicial removal of a covenant restricting use of her land?